SCHEMBL236154

SCHEMBL236154

Cc1cc2ncc3cc(-c4ccccc4)c(-c4ccc(NS(C)(=O)=O)cc4)nc3n2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.44
HSP90AA1 P07900 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
AURKA O14965 1/20 0.43
KLK7 P49862 1/20 0.41
CYP17A1 P05093 1/20 0.40
PKM P14618 1/20 0.39
KDR P35968 1/20 0.39
FYN P06241 1/20 0.38
PTGS2 P35354 3/20 0.38
ALOX5 P09917 1/20 0.38
HAVCR2 Q8TDQ0 1/20 0.38
AKT1 P31749 1/20 0.38
AKT2 P31751 1/20 0.38
KMT2A Q03164 1/20 0.38
PDE10A Q9Y233 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL237338 0.83 KDR (0.48) ALDH1A1KDM4ELMNAMAPTHPGD
SCHEMBL235451 0.82 NPC1 (0.46) ALDH1A1KDM4EMAPTHPGDAURKA
SCHEMBL235955 0.82 AURKA (0.41) HPGDAURKAPKMKDRAKT1
SCHEMBL238251 0.81 AKT1 (0.47) HPGDAURKAFYNAKT1AKT2
SCHEMBL16986811 0.80 AKT1 (0.40) HPGDAURKAPKMKDRAKT1
SCHEMBL234236 0.80 NPC1 (0.41) ALDH1A1KDM4EMAPTHPGDAURKA
SCHEMBL239466 0.79 NPC1 (0.41) ALDH1A1KDM4EMAPTHPGDAURKA
SCHEMBL18797689 0.79 NPC1 (0.41) ALDH1A1KDM4EMAPTHPGDAURKA
SCHEMBL237401 0.79 AKT1 (0.53) AKT1AKT2KMT2A
SCHEMBL238314 0.78 CYP2C9 (0.44) ALDH1A1KDM4EMAPTHPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP claimed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US claimed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US claimed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 ALDH1A1 3980/4885KDM4E 2166/4885LMNA 2724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.